Unchanged pharmacokinetics of VP-16-213 (etoposide,NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide |
| |
| Affiliation: | 1. Department of Oncology, Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands;2. Department of Pulmonology, Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands;1. Health Sciences Centre, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada;2. Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada;1. Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven – University of Leuven, Leuven, Belgium;3. Translational Research in GastroIntestinal Disorders, Department of Clinical and Experimental Medicine, KU Leuven – University of Leuven, Leuven, Belgium;4. Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven – University of Leuven, Leuven, Belgium;1. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;2. Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands;3. Department of Pharmaceutical Sciences, St Jude Children’s Research Hospital, Memphis, TN, United States |
| |
| Abstract: | ![]()
In patients with small-cell lung cancer VP-16-213 is often given in combination with doxorubicin and cyclophosphamide. Little is known about possible interactions between these drugs. Therefore we investigated in 7 patients the pharmacokinetics of VP-16-213, with and without the other two drugs.We found no change in the pharmacokinetics. We also provide evidence that the pharmacokinetics did not change in two sequential administrations of the drug.Pharmacokinetic data are in agreement with previous reports. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
